Dawn Sauro appointed to Chief Operating Officer at Elligo Health

Elligo Health Research has announced that Dawn Sauro has been named Chief Operating Officer (COO), with the aim of furthering the company’s growth, efficiency and mission of optimising the intersection of healthcare and research through methods including new technology, custom research practice methods and direct access to patients.
Elligo Health is a healthcare-enabling research organisation that accelerates clinical trials and has access to over 150 million patients and their HIPAA-compliant healthcare data. Sauro has previously worked as executive vice president of Research Strategy at Elligo, and brings more than 30 years of drug and device development experience to her new role.
Before joining Elligo, Sauro worked as chief development officer at Clinpace Clinical Research (now known as Caidya), during this role she grew the organisation so it became a trusted partner for various sponsors across a range of therapy areas.
Commenting on Sauro’s appointment, Elligo’s CEO John Potthoff, said “Dawn is a drug development and clinical research business leader with deep subject matter expertise across a broad spectrum of therapeutic areas, but specifically brings vast knowledge in haematology and oncology. She is a valued member of company leadership with decades of industry insight, client relationships and an understanding of unique needs that help sponsors and clinical research sites drive results.”
Sauro added: “I look forward to continuing in this new leadership role with Elligo, but also continuing to focus on delivering outcomes that move us all closer to our ultimate goal – providing everyone with easier access to participate in clinical research.”